Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Nihon Chouzai Co ( (JP:3341) ) has shared an update.
Nihon Chouzai Co., Ltd. announced significant extraordinary losses for the fiscal year ending March 31, 2025, due to impairment losses in its Dispensing Pharmacy Business, totaling 4,132 million yen. The company also reported a shortfall in its consolidated earnings compared to its forecast, attributed to lower prescription volumes and manufacturing issues at its Kawauchi Plant, impacting sales and profitability.
More about Nihon Chouzai Co
Nihon Chouzai Co., Ltd. operates in the healthcare sector, primarily focusing on the Dispensing Pharmacy Business and the Pharmaceutical Manufacturing and Sales Business. The company is involved in the production and sale of generic drugs through its group company, Choseido Pharmaceutical.
YTD Price Performance: 0.25%
Technical Sentiment Signal: Strong Sell
Current Market Cap: $602.7M
See more data about 3341 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue